Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from PAVmed ( (PAVM) ).
On September 11, 2025, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., completed a public offering of 28,750,000 shares of its common stock at $1.00 per share, raising approximately $26.9 million after expenses. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.
The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
PAVmed’s overall stock score reflects significant financial challenges, despite some positive strategic initiatives and an attractive valuation. The company’s ability to address profitability and liquidity issues will be crucial for future performance.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
PAVmed Inc. operates in the medical device industry through its subsidiary Lucid Diagnostics Inc., which focuses on diagnostic technologies.
Average Trading Volume: 212,846
Technical Sentiment Signal: Sell
Current Market Cap: $9.15M
For an in-depth examination of PAVM stock, go to TipRanks’ Overview page.